REGISTER
ESMO 2026 Previews: Chinese Studies in HER2 Gastric Cancer, Rectal, CAR-T, and BTC
Four Chinese studies in gastrointestinal oncology were previewed ahead of the ESMO 2026 Annual Meeting in Madrid. They include a phase 2 trial of the HER2 bispecific ADC TQB2102 plus bemotrizumab in HER2-positive gastric cancer, the phase 3 UNION trial of neoadjuvant short-course radiotherapy plus camrelizumab in rectal cancer, a phase 1 update of GPC3-targeted armored CAR-T C-CAR031 in advanced HCC, and a phase 3 trial of subcutaneous envafolimab plus GEMOX in advanced biliary tract cancer.

The ESMO 2026 Annual Meeting will be held Oct 23 to 27, 2026, in Madrid, Spain. As the meeting approaches, abstracts from Chinese investigators in gastrointestinal oncology continue to be released. Late-breaking abstracts (LBAs) have not yet been announced and will be presented during the meeting.

All four studies below were presented as conference abstracts and were not yet peer-reviewed at the time of this report.

Article Key Points

- Meeting: ESMO 2026 Annual Meeting, Oct 23-27, 2026, Madrid, Spain; latest breaking abstracts not yet released

- TQB2102 (HER2 bispecific ADC, DAR 6) plus bemotrizumab with or without capecitabine, phase 2, n=86 in 3 cohorts

- TQB2102 triples had higher ORR and DCR than the doublet; 6 mg/kg dose performed best, selected for phase 3

- UNION phase 3, n=231: short-course radiotherapy plus camrelizumab improved 3-year EFS, 91.3% vs 77.4% (HR 0.33)

- C-CAR031 (GPC3 CAR-T with TGF-beta receptor II dominant-negative), phase 1, n=36: ORR 44%, DCR 92%, CRS 94%

- Envafolimab (subcutaneous anti-PD-L1) plus GEMOX, phase 3, n=462 treated: OS 10.9 vs 8.6 months (HR 0.723)

- Safety: grade 3+ TRAEs 56%-61% (TQB2102), 51.3% vs 48.2% (UNION), CRS 94% (C-CAR031)

- Evidence status: conference abstracts; full results have not yet been peer-reviewed

Abstract 2876RO

TQB2102, a Novel HER2 Bispecific Antibody-Drug Conjugate, Combined with Bemotrizumab with or without Capecitabine as First-Line Therapy for HER2-Positive Advanced Gastric/Gastroesophageal Junction Cancer: A Phase II Study

Presenter: Miaozhen Qiu, Sun Yat-sen University Cancer Center

This multicenter phase 2 trial evaluated the efficacy and safety of TQB2102, a novel HER2 bispecific antibody-drug conjugate, combined with bemotrizumab, with or without capecitabine, as first-line therapy for HER2-positive advanced gastric or gastroesophageal junction cancer (GC/GEJC). TQB2102 targets domains 2 and 4 of HER2 and is conjugated to a deuterated topoisomerase I inhibitor, with a drug-to-antibody ratio (DAR) of 6.

The trial enrolled patients with unresectable locally advanced or metastatic GC/GEJC who had not received prior systemic therapy and had an ECOG performance status of 0 to 1. Three cohorts were defined: cohort A (TQB2102 7.5 mg/kg plus bemotrizumab), cohort B (7.5 mg/kg plus bemotrizumab plus capecitabine), and cohort C (6 mg/kg plus bemotrizumab plus capecitabine). The primary endpoint was objective response rate (ORR); secondary endpoints included disease control rate (DCR), time to response, duration of response, progression-free survival (PFS), overall survival (OS), and safety.

As of Feb 28, 2026, 86 patients had been enrolled (25 in cohort A, 37 in cohort B, and 24 in cohort C). The three-drug cohorts (B and C) had higher ORR and DCR and a shorter time to response than the doublet cohort (A). Median PFS and OS were not reached in any cohort, but the three-drug cohorts had better 6-month PFS rates and 9-month OS rates. Within the three-drug cohorts, the 6 mg/kg dose showed better activity, and consistent antitumor activity was observed across PD-L1 subgroups.

Safety, Grade 3 or higher treatment-related adverse events (TRAEs) occurred in 56% of the doublet cohort and 60.66% of the three-drug cohorts (41.67% in cohort C and 72.97% in cohort B). All events were manageable and reversible. The study identified 6.0 mg/kg as the recommended phase 3 dose, and a phase 3 trial is planned.

Abstract 3530O

Neoadjuvant Short-Course Radiotherapy Followed by Camrelizumab and Chemotherapy in Locally Advanced Rectal Cancer: The Phase 3 UNION Trial

Presenter: Zhenyu Lin, Cancer Center, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology

This is the first phase 3 trial worldwide to evaluate a neoadjuvant strategy combining radiotherapy, immunotherapy, and chemotherapy for locally advanced rectal cancer (LARC), and this report presents the prespecified event-free survival (EFS) analysis. Most patients with LARC are proficient in mismatch repair or microsatellite stable (pMMR/MSS), and effective immunotherapy strategies have been limited for this population.

The trial enrolled patients with rectal adenocarcinoma classified as cT3-4 or node-positive (N+), with tumor within 10 cm of the anal verge. Patients were randomized 1:1 to the experimental arm, which received short-course radiotherapy (25 Gy in 5 fractions) followed by camrelizumab plus capecitabine and oxaliplatin (CAPOX), or the control arm, which received long-course chemoradiotherapy (50.4 Gy in 28 fractions with concurrent capecitabine) followed by CAPOX. Both arms received 2 cycles of neoadjuvant and 6 cycles of adjuvant CAPOX; the experimental arm additionally received camrelizumab (200 mg, day 1) for up to 17 cycles.

The primary endpoint was pathological complete response rate assessed by a blinded independent review committee (BIRC); key secondary endpoints were investigator-assessed EFS and overall survival.

Between July 2021 and March 2023, 231 patients were randomized (113 to the experimental arm and 118 to the control arm). As of Oct 1, 2025, median follow-up was 36.8 and 35.6 months respectively. The experimental arm had a significantly higher 3-year EFS rate than the control arm (91.3% vs 77.4%, HR 0.33, 95% CI 0.15-0.71, P=0.0029), with consistent results by BIRC assessment. Grade 3 or higher treatment-related adverse events were comparable between groups (51.3% vs 48.2%). This is the first report that an immunotherapy regimen significantly improved EFS in patients with LARC, and this neoadjuvant strategy may become a new standard of care.

Abstract 1680RO

Phase I Study of C-CAR031, a GPC3-Targeted TGF-beta Receptor II Dominant-Negative Armored Autologous CAR-T, in Advanced Hepatocellular Carcinoma: Updated Results

Presenter: Qi Zhang, First Affiliated Hospital of Zhejiang University School of Medicine

This first-in-human, open-label, dose-escalation phase 1 trial reports updated results for C-CAR031, a GPC3-targeted armored autologous CAR-T, in advanced hepatocellular carcinoma (aHCC). C-CAR031 carries a dominant-negative transforming growth factor beta receptor II, intended to overcome TGF-beta-mediated immunosuppression in the tumor microenvironment.

The trial enrolled GPC3-positive patients with aHCC who had progressed after at least one line of systemic therapy. Following standard lymphodepletion, C-CAR031 was administered intravenously using an accelerated titration combined with a 3+3 design. The primary endpoints were safety and tolerability.

As of March 25, 2026, 36 patients had received treatment across 4 dose levels, with median follow-up of 14 months. Ninety-four percent had advanced-stage disease, and 83% had extrahepatic metastasis. The median number of prior treatment lines was 4, and 92% had previously received both an immune checkpoint inhibitor and a tyrosine kinase inhibitor.

For safety, 94% of patients developed cytokine release syndrome (CRS), with 6% experiencing grade 3 CRS at dose level 4. No immune effector cell-related neurotoxicity syndrome or dose-limiting toxicity was observed. Common grade 3 or higher adverse events were lymphopenia, leukopenia, and neutropenia. Two patients (6%) developed interstitial lung disease at dose level 4, and one patient died from renal insufficiency secondary to tumor lysis syndrome after declining dialysis.

For activity, 89% of patients had tumor shrinkage, with a median reduction of 42% (range 3%-94%). The DCR was 92% and the ORR was 44%. Updated survival data will be presented at the meeting. The results indicate that C-CAR031 has a manageable safety profile and consistent activity, and further development is ongoing.

Abstract 473RO

Subcutaneous Anti-PD-L1 Monoclonal Antibody Envafolimab Plus GEMOX Versus GEMOX Alone as First-Line Treatment for Advanced Biliary Tract Cancer in Chinese Patients: A Randomized, Open-Label, Multicenter, Registrational Phase III Trial

Presenter: Shukui Qin, Zhejiang Qiantang Advanced Institute

This randomized, open-label, multicenter, registrational phase 3 trial evaluated the efficacy and safety of subcutaneous anti-PD-L1 monoclonal antibody envafolimab plus gemcitabine and oxaliplatin (GEMOX) versus GEMOX alone as first-line treatment for advanced biliary tract cancer (BTC) in Chinese patients.

The trial enrolled treatment-naive patients with unresectable locally advanced or metastatic BTC. Patients were randomized 1:1 to receive envafolimab (2.5 mg/kg, once weekly by subcutaneous injection) plus GEMOX (gemcitabine 1,000 mg/m2 on days 1 and 8, oxaliplatin 85 mg/m2 on day 1, every 3 weeks) or GEMOX alone. Chemotherapy was given for up to 6 cycles, with stratification by site of primary tumor, disease stage, prior therapy, and ECOG performance status. The primary endpoint was overall survival (OS).

A total of 472 patients were randomized and 462 received treatment (232 in the combination arm and 230 in the chemotherapy arm). OS was significantly improved in the combination arm (median 10.9 vs 8.6 months, HR 0.723, 95% CI 0.585-0.880, P=0.0016). OS rates at 12, 24, and 36 months were 44.2% vs 29.9%, 19.9% vs 10.8%, and 12.5% vs 7.7%, respectively. ORR was 27.6% vs 20.9%, and median duration of response was 5.5 vs 4.2 months.

For safety, immune-related adverse events occurred in 20.7% of the combination arm, and overall tolerability was good with no new safety signal. The results indicate that envafolimab plus GEMOX provides a significant OS benefit together with the convenience of subcutaneous administration, and may become a first-line standard for advanced BTC.

Closing Note

This preview covers a selection of gastrointestinal oncology abstracts from Chinese investigators. Additional reports from the ESMO 2026 meeting will be covered during the meeting itself.

Evidence status: all studies described here were released as conference abstracts ahead of the meeting. Latest breaking abstracts had not been announced at the time of this report, and full results have not yet been peer-reviewed.

0
0
Loading